Tumor microenvironment and drug resistance in hematologic malignancies

Blood Reviews

Volumn 20, Issue 6, 2006, Pages 333-342

  Li, Zhi Wei ^a   Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

CAM DR; Cell adhesion; Drug resistance; EM DR; SM DR; Tumor microenvironment

Indexed keywords

CYTARABINE; DOXORUBICIN; MELPHALAN; MITOXANTRONE; PATUPILONE; PROTEIN ANTIBODY; STABILIZING AGENT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CANCER RESISTANCE; CELL ADHESION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; HEMATOLOGIC MALIGNANCY; HUMAN; MICROENVIRONMENT; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL;

CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HEMATOLOGIC NEOPLASMS; HUMANS; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION;

EID: 33750631842     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2005.08.003     Document Type: Article

References (80)

1. Hazlehurst L.A., Landowski T.H., and Dalton W.S. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 22 47 (2003) 7396-7402
2. Lagneaux L., Delforge A., Bron D., De Bruyn C., and Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91 7 (1998) 2387-2396
3. Dias S., Choy M., Alitalo K., and Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99 6 (2002) 2179-2184
4. Menzel T., Rahman Z., Calleja E., et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 87 3 (1996) 1056-1063
5. Burger J.A., Burger M., and Kipps T.J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94 11 (1999) 3658-3667
6. Kawano M., Hirano T., Matsuda T., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332 6159 (1988) 83-85
7. Xu W., Liu L., Smith G.C., and Charles G. Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat Cell Biol 2 6 (2000) 339-345
8. Jiang X., Lopez A., Holyoake T., Eaves A., and Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA 96 22 (1999) 12804-12809
9. Rambaldi A., Wakamiya N., Vellenga E., et al. Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. J Clin Invest 81 4 (1988) 1030-1035
10. Young D.C., Wagner K., and Griffin J.D. Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J Clin Invest 79 1 (1987) 100-106
11. Novak A.J., Darce J.R., Arendt B.K., et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103 2 (2004) 689-694
12. Kern C., Cornuel J.F., Billard C., et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103 2 (2004) 679-688
13. Oshiro M.M., Landowski T.H., Catlett-Falcone R., et al. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res 7 12 (2001) 4262-4271
14. Ling V., Gerlach J., and Kartner N. Multidrug resistance. Breast Cancer Res Treat 4 2 (1984) 89-94
15. Durig J., Schmucker U., and Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 15 5 (2001) 752-756
16. Moller C., Stromberg T., Juremalm M., Nilsson K., and Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 17 1 (2003) 203-210
17. Testa U., Riccioni R., Diverio D., Rossini A., Lo Coco F., and Peschle C. Interleukin-3 receptor in acute leukemia. Leukemia 18 2 (2004) 219-226
18. Fielder W., Graeven U., Ergun S., et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 11 8 (1997) 1234-1237
19. Bellamy W.T., Richter L., Frutiger Y., and Grogan T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59 3 (1999) 728-733
20. Dias S., Hattori K., Zhu Z., et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106 4 (2000) 511-521
21. Dias S., Shmelkov S.V., Lam G., and Rafii S. VEGF (165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99 7 (2002) 2532-2540
22. Jeltsch M., Kaipainen A., Joukov V., et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276 5317 (1997) 1423-1425
23. Konig A., Menzel T., Lynen S., et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11 2 (1997) 258-265
24. Brogi E., Wu T., Namiki A., and Isner J.M. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 90 2 (1994) 649-652
25. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., and Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96 8 (2000) 2655-2663
26. Klein B., Zhang X.G., Lu Z.Y., and Bataille R. Interleukin-6 in human multiple myeloma. Blood 85 4 (1995) 863-872
27. Catlett-Falcone R., Landowski T.H., Oshiro M.M., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 1 (1999) 105-115
28. Gaillard J.P., Bataille R., Brailly H., et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 23 4 (1993) 820-824
29. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 Pt 1 (2003) 1-20
30. Stamler J.S. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 78 6 (1994) 931-936
31. Zhao H., Dugas N., Mathiot C., et al. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 92 3 (1998) 1031-1043
32. Secchiero P., Gonelli A., Celeghini C., et al. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood 98 7 (2001) 2220-2228
33. Deininger M.W., Goldman J.M., and Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 96 10 (2000) 3343-3356
34. Zhang X., and Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92 10 (1998) 3829-3840
35. Mayerhofer M., Valent P., Sperr W.R., Griffin J.D., and Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100 10 (2002) 3767-3775
36. Wong S., McLaughlin J., Cheng D., Shannon K., Robb L., and Witte O.N. IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. Proc Natl Acad Sci USA 100 20 (2003) 11630-11635
37. Mackay F., Schneider P., Rennert P., and Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21 (2003) 231-264
38. Moreaux J., Legouffe E., Jourdan E., et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103 8 (2004) 3148-3157
39. Majka M., Janowska-Wieczorek A., Ratajczak J., et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34 (+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 97 10 (2001) 3075-3085
40. Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodiLeukemia. Leukemia 18 1 (2004) 1-10
41. Klein B., Tarte K., Jourdan M., et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 78 2 (2003) 106-113
42. Chauhan D., and Anderson K.C. Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis 8 4 (2003) 337-343
43. Ishikawa H., Tsuyama N., Abroun S., et al. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation. Leuk Lymphoma 44 9 (2003) 1477-1481
44. Dalton W.S. The tumor microenvironment: focus on myeloma. Cancer Treat Rev 29 Suppl 1 (2003) 11-19
45. Shain K.H., Landowski T.H., and Dalton W.S. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 168 5 (2002) 2544-2553
46. Hazlehurst L.A., Valkov N., Wisner L., et al. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98 6 (2001) 1897-1903
47. Miranti C.K., and Brugge J.S. Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol 4 4 (2002) E83-E90
48. Jensen G.S., Belch A.R., Mant M.J., Ruether B.A., Yacyshyn B.R., and Pilarski L.M. Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am J Hematol 43 1 (1993) 29-36
49. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., and Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93 5 (1999) 1658-1667
50. Damiano J.S., and Dalton W.S. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 38 1-2 (2000) 71-81
51. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69 1 (1992) 11-25
52. Durand R.E., and Sutherland R.M. Effects of intercellular contact on repair of radiation damage. Exp Cell Res 71 1 (1972) 75-80
53. Desoize B., and Jardillier J. Multicellular resistance: a paradigm for clinical resistance?. Crit Rev Oncol Hematol 36 2-3 (2000) 193-207
54. Landowski T.H., Olashaw N.E., Agrawal D., and Dalton W.S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 22 16 (2003) 2417-2421
55. Khwaja A., Rodriguez-Viciana P., Wennstrom S., Warne P.H., and Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. Embo J 16 10 (1997) 2783-2793
56. Yamada K.M., and Even-Ram S. Integrin regulation of growth factor receptors. Nat Cell Biol 4 4 (2002) E75-E76
57. Reginato M.J., Mills K.R., Paulus J.K., et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 5 8 (2003) 733-740
58. Hazlehurst L.A., Enkemann S.A., Beam C.A., et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 63 22 (2003) 7900-7906
59. Mahtouk K., Jourdan M., De Vos J., et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 103 5 (2004) 1829-1837
60. Hazlehurst L.A., Damiano J.S., Buyuksal I., Pledger W.J., and Dalton W.S. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19 38 (2000) 4319-4327
61. Jiang Y., Prosper F., and Verfaillie C.M. Opposing effects of engagement of integrins and stimulation of cytokine receptors on cell cycle progression of normal human hematopoietic progenitors. Blood 95 3 (2000) 846-854
62. de la Fuente M.T., Casanova B., Garcia-Gila M., Silva A., and Garcia-Pardo A. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 13 2 (1999) 266-274
63. Mudry R.E., Fortney J.E., York T., Hall B.M., and Gibson L.F. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 96 5 (2000) 1926-1932
64. Matsunaga T., Takemoto N., Sato T., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9 9 (2003) 1158-1165
65. Zhang Z., Vuori K., Reed J.C., and Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 92 13 (1995) 6161-6165
66. Matter M.L., and Ruoslahti E. A signaling pathway from the alpha5beta1 and alpha (v)beta3 integrins that elevates bcl-2 transcription. J Biol Chem 276 30 (2001) 27757-27763
67. Bendall L.J., Makrynikola V., Hutchinson A., Bianchi A.C., Bradstock K.F., and Gottlieb D.J. Stem cell factor enhances the adhesion of AML cells to fibronectin and augments fibronectin-mediated anti-apoptotic and proliferative signals. Leukemia 12 9 (1998) 1375-1382
68. Pulido R., Elices M.J., Campanero M.R., et al. Functional evidence for three distinct and independently inhibitable adhesion activities mediated by the human integrin VLA-4. Correlation with distinct alpha*4 epitopes. J Biol Chem 266 16 (1991) 10241-10245
69. Fortney J.E., Zhao W., Wenger S.L., and Gibson L.F. Bone marrow stromal cells regulate caspase 3 activity in leukemic cells during chemotherapy. Leuk Res 25 10 (2001) 901-907
70. Nefedova Y., Landowski T.H., and Dalton W.S. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17 6 (2003) 1175-1182
71. Nefedova Y., Cheng P., Alsina M., Dalton W.S., and Gabrilovich D.I. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 103 9 (2004) 3503-3510
72. Tohda S., and Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma 42 3 (2001) 467-472
73. Jundt F., Anagnostopoulos I., Forster R., Mathas S., Stein H., and Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 99 9 (2002) 3398-3403
74. Ellisen L.W., Bird J., West D.C., et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66 4 (1991) 649-661
75. Aster J.C., and Pear W.S. Notch signaling in leukemia. Curr Opin Hematol 8 4 (2001) 237-244
76. Cheng P., Zlobin A., Volgina V., et al. Notch-1 regulates NF-kappaB activity in hemopoietic progenitor cells. J Immunol 167 8 (2001) 4458-4467
77. Houde C, Li Y, Song L, et al. Over-expression of the NOTCH Ligand JAG2 in Malignant Plasma Cells from Multiple Myeloma Patients and Cell Lines. Blood. Aug 3 2004.
78. Freund G.G., Kulas D.T., Way B.A., and Mooney R.A. Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines. Cancer Res 54 12 (1994) 3179-3185
79. Freund G.G., Kulas D.T., and Mooney R.A. Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol 151 4 (1993) 1811-1820
80. Lin B, Catley L, LeBlanc R, et al. Patupilone (Epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood. Sep 14 2004.